Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- VIVE.ST
- Price
- 0.24
- Stock movement up
- +0.00 (1.50%)
- Company name
- Vivesto AB
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 127.52M
- Ent value
- 143.14M
- Price/Sales
- -
- Price/Book
- 0.71
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -19.04%
- 1 year return
- -24.88%
- 3 year return
- -46.99%
- 5 year return
- -50.79%
- 10 year return
- -32.39%
Last updated: 2025-04-12
DIVIDENDS
VIVE.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 0.71 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 538.04M |
| EPS (TTM) | -0.18 |
| FCF per share (TTM) | -0.10 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -108.74M |
| Net income (TTM) | -98.92M |
| EPS (TTM) | -0.18 |
| EPS (1y forward) | -0.08 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 2.91M |
| Net receivables | 0.00 |
| Total current assets | 58.81M |
| Goodwill | 0.00 |
| Intangible assets | 138.50M |
| Property, plant and equipment | 0.00 |
| Total assets | 197.61M |
| Accounts payable | 5.48M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 18.53M |
| Total liabilities | 18.53M |
| Shareholder's equity | 179.08M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -55.37M |
| Capital expenditures (TTM) | 213.00K |
| Free cash flow (TTM) | -55.59M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -55.24% |
| Return on Assets | -50.06% |
| Return on Invested Capital | -55.24% |
| Cash Return on Invested Capital | -31.04% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.23 |
| Daily high | 0.24 |
| Daily low | 0.22 |
| Daily Volume | 182K |
| All-time high | 18.45 |
| 1y analyst estimate | 0.42 |
| Beta | 0.54 |
| EPS (TTM) | -0.18 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 21 May 2025 |
Downside potential
Loading...
Downside potential data
| VIVE.ST | S&P500 | |
| Current price drop from All-time high | -98.72% | -12.89% |
| Highest price drop | -99.09% | -56.47% |
| Date of highest drop | 6 Dec 2023 | 9 Mar 2009 |
| Avg drop from high | -69.00% | -11.07% |
| Avg time to new high | 621 days | 12 days |
| Max time to new high | 2806 days | 1805 days |
COMPANY DETAILS
Marketcap
127.52M
Marketcap category
Small-cap
Description
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.
Employees
4
Website
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
As European markets navigate a landscape marked by hopes of increased government spending and trade-related uncertainties, the pan-European STOXX Europe 600 Index recently ended higher after two weeks...
March 24, 2025